UNSPSC 51433919: Lercanidipine

This classification denotes a calcium channel blocker with the molecular formula C36H41N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7XTJ4R0BH, chemically known as (+-)-2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as lercanidipine, which bears US NIH Compound Identifier 65866. European Medicines Agency schedules Lercanidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08437MIG.

UNSPSC 51433919 Lercanidipine, a Commodity code, nominally names a single antihypertensive pharmaceutical, but recent state and local solicitations tagged under this code actually span a much broader pharmaceutical procurement landscape — emergency medications, generic multi-source drugs, and prescription-fulfillment infrastructure. The work being solicited includes supply of specific advanced life support medications (epinephrine, adenosine, diltiazem, and labetalol formulations) for emergency response, generic pharmaceutical and OTC product distribution through cooperative purchasing networks, and market research into direct-to-manufacturer prescription models for state health and human services programs. Issuing bodies include city fire and rescue services (Tampa Fire Rescue through the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). The scope reflects a mix of emergency-response medical supply procurement, routine pharmaceutical warehousing and distribution, and strategic program redesign at the state level.

Recent activity spans Florida, Texas, and Minnesota as primary states of record. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026, with a response deadline of April 8, 2026 — a compressed timeline — to supply Advanced Life Support Medications (estimated value $40,000) for Tampa Fire Rescue, requiring nine-month minimum expiration dates and ten-day delivery. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (Solicitation S1070000015802) due March 26, 2026, seeking generic multi-source pharmaceutical and OTC product manufacturers to supply through three authorized wholesalers with an effective date of July 1, 2026, weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, functioning as market intelligence gathering before formal solicitation. The Tampa opportunity carries an SLBE sheltered-market designation with a 5 percent bid discount capped at $10,000; the Minnesota RFP does not identify set-aside restrictions and reserves multi-award rights based on therapeutic and patient-safety considerations.